Biblio
Export 550 results:
Author Title Type [ Year] Filters: Keyword is Alzheimer Disease [Clear All Filters]
“Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.”, Neurology, vol. 74, no. 3, pp. 201-9, 2010.
, “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways.”, Proc Natl Acad Sci U S A, vol. 107, no. 28, pp. 12698-703, 2010.
, “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
, “Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.”, PLoS One, vol. 5, no. 11, p. e13950, 2010.
, “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
, “National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline.”, Ann Intern Med, vol. 153, no. 3, pp. 176-81, 2010.
, “Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy.”, J Alzheimers Dis, vol. 19, no. 1, pp. 355-61, 2010.
, “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
, “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”, Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 263-9, 2011.
, “The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 270-9, 2011.
, “Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons.”, Cell, vol. 146, no. 3, pp. 359-71, 2011.
, “Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.”, Lancet Neurol, vol. 10, no. 2, pp. 187-98, 2011.
, “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
, “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
, “Neuronal activity regulates the regional vulnerability to amyloid-β deposition.”, Nat Neurosci, vol. 14, no. 6, pp. 750-6, 2011.
, “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
, “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
, “Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease.”, Neurology, vol. 76, no. 17, pp. 1485-91, 2011.
,